In a new report, analysts at the investment bank Cowen highlight a marijuana and hemp compound called CBD as a massive opportunity for growth.
In the healthcare realm, the analysts noted that on the heels of the recent FDA approval of Epidiolex, more companies could be working on similar products. Canadian marijuana producerCBD products are also gaining a presence in independent pharmacies — the non-Walgreens or CVSs of the world — where they are already selling or have plans to sell CBD oil.
And although large pharmacy chains like CVS are not currently selling CBD, they may do so in the future. The analysts note that the US holding company behind Walgreens, known as the Walgreens Boots Alliance, for example, has indicated that it is monitoring the CBD market.A drug derived from marijuana has become the first to win federal approval, and experts predict an avalanche effect
Lab-grown CBD and THC have gained a lot of recent interest from startups in recent years. The process would use a technique known as synthetic biology or biosynthesis to coax genetically altered organisms like yeast into churning out the marijuana compounds. Doing so, the analysts write, could save manufacturers money and time.with Canadian cannabis company Cronos to make compounds like THC and CBD in a lab.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Wall Street Is Gushing Over Palo Alto Stock After Earnings Crushed EstimatesThe cybersecurity company crushed Wall Street profit expectations and reported fiscal second-quarter adjusted earnings per share of $1.51 versus the $1.22 consensus. It also gave sales guidance for its fiscal-third-quarter above the average analyst projection.
Read more »
Wall Street edges lower after Lighthizer comments on trade talksWall Street's main indexes edged lower on Wednesday after U.S. trade repres...
Read more »
GE shares jump again as Wall Street loves Danaher deal: Stock no longer has 'downside risk'A day after General Electric's surprise announcement of a biopharma sale to Danaher, Wall Street crowed about the embattled industrial conglomerate's $21.4 billion deal.
Read more »
Mylan quarterly profit, 2019 forecast miss Wall Street estimates -- stock tanksGeneric drugmaker Mylan on Tuesday reported lower-than-expected fourth-quarter profit and forecast 2019 earnings well below Wall Street estimates, as it grapples with significant problems at its Morgantown, West Virginia, plant.
Read more »
Lowe's shares dip as sales fall short of Wall Street expectationsLowe's on Wednesday delivered a mixed earnings report for the fourth quarter, sending its shares slightly lower in premarket trading.
Read more »
Frackers Face Harsh Reality as Wall Street Backs AwayThe once-powerful partnership between fracking companies and Wall Street is fraying as the industry struggles to attract investors after nearly a decade of losing money.
Read more »
Apple, Goldman Tie-Up Is Latest Way for Silicon Valley to Reshape Wall StreetApple wants a piece of banking. Goldman doesn’t want to give it away. But both companies need each other if they are going to burrow deeper into consumer banking.
Read more »